GC Biopharma Corp. (KRX:006280)
South Korea · Delayed Price · Currency is KRW | Market Cap | 1.49T +1.5% |
| Revenue (ttm) | 1.96T +9.7% |
| Net Income | -49.90B |
| EPS | -4,372.28 |
| Shares Out | 11.41M |
| PE Ratio | n/a |
| Forward PE | 6.89 |
| Dividend | 1,500.00 (1.15%) |
| Ex-Dividend Date | Mar 30, 2026 |
| Volume | 9,532 |
| Open | 129,100 |
| Previous Close | 129,100 |
| Day's Range | 129,000 - 132,700 |
| 52-Week Range | 105,900 - 183,800 |
| Beta | 0.68 |
| Analysts | Buy |
| Price Target | 191,000.00 (+46.14%) |
| Est. Earnings | Nov 13, 2026 |
About GC Biopharma
GC Biopharma Corp., a biopharmaceutical company, develops and sells pharmaceutical drugs in South Korea, India, Taiwan, Japan, China, Malaysia, and internationally. It provides over-the-counter drugs, such as Acustop Cataplasma for Analgesic and anti-inflammatory effect; Kenhancer plaster for anti-inflammatory; and Zenol Cool Type and Zenol Mild Hot Type drugs to treat anti-inflammatory and pain relief. The company also offers Albumin-GCC injection (inj.) for hypoalbuminemia and shock in acute hemorrhage, as well as low synthesis of albumin; An... [Read more]
Full Company ProfileFinancial Performance
In 2025, GC Biopharma's revenue was 1.99 trillion, an increase of 18.54% compared to the previous year's 1.68 trillion. Losses were -4.67 billion, -82.22% less than in 2024.
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for 006280 stock is "Buy." The 12-month stock price target is ₩191,000, which is an increase of 46.14% from the latest price.
News
MedGenome Makes a Majority Investment in Leading Gujarat-Based Diagnostics Chain Green Cross to Expand Genomics Offerings Across India
Business Wire India This partnership brings together the legacy of trusted diagnostics along with the combined network, infrastructure, science, technology,...